Key Segments:
By Drug Class
-
Biguanides
-
SGLT-2 Inhibitors
-
DPP-4 Inhibitors
-
Sulfonylureas
-
Others
By Distribution Channel
-
Retail Pharmacies
-
Hospital Pharmacies
-
Online Pharmacies
By End User
-
Hospitals
-
Specialty Clinics
-
Homecare Settings
By Age Group
-
Adult
-
Geriatric
-
Pediatric
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market includes Eli Lilly, Novo Nordisk, AstraZeneca, Merck, Sanofi, Boehringer Ingelheim, Takeda, Novartis, Teva, Sun Pharma, Lupin and Zydus, among others.
The main opportunities lie in fixed-dose combination tablets that simplify multi-drug regimens, and in expanding generics manufacturing and distribution partnerships across emerging markets.
The key growth factor is rising global diabetes prevalence, reinforced by an expanding wave of generic approvals lowering treatment cost across major drug classes.
By drug class, the Biguanides segment dominated the market with approximately 45.00% share in 2025, reflecting its established first-line clinical use and broad generic availability.
North America dominated the market with approximately 38.00% share in 2025, supported by a large diabetic patient population and rapid generic drug approvals.
